Literature DB >> 12955214

[PET and SPECT investigations in Alzheimer's disease].

S Asenbaum1.   

Abstract

Nuclear medicine offers a wide range of possibilities to investigate dementia. Various SPECT and PET tracers will be introduced in this article first. Different questions concerning evaluation of dementia are discussed taking Alzheimer's disease (AD) as an example. It is important to perform nuclear medicine investigations on high technical level, using standardized methods as statistical parametric mapping (SPM) for evaluation. If neuroprotective therapies are available, an early diagnosis, the determination of risk factors and longitudinal investigations will be the focus of interest and the main goal of nuclear medicine. Apart from measuring cerebral perfusion and glucose metabolism the development of new ligands, concerning the cholinergic system and the visualization of amyloid plaques, is of great importance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955214     DOI: 10.1007/s00117-003-0919-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  54 in total

1.  SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

Authors:  W Jagust; R Thisted; M D Devous; R Van Heertum; H Mayberg; K Jobst; A D Smith; N Borys
Journal:  Neurology       Date:  2001-04-10       Impact factor: 9.910

2.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

4.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

5.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

6.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography.

Authors:  Y Samson; P Hantraye; J C Baron; F Soussaline; D Comar; M Mazière
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

Review 7.  Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies.

Authors:  Michael D Devous
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-25       Impact factor: 9.236

8.  Age, sex and laterality effects on cerebral glucose metabolism in healthy adults.

Authors:  Mark W Willis; Terence A Ketter; Tim A Kimbrell; Mark S George; Peter Herscovitch; Aimee L Danielson; Brenda E Benson; Robert M Post
Journal:  Psychiatry Res       Date:  2002-02-15       Impact factor: 3.222

9.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

10.  Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

Authors:  Nobuyuki Okamura; Hiroyuki Arai; Masahiro Maruyama; Makoto Higuchi; Toshifumi Matsui; Haruko Tanji; Takashi Seki; Hisao Hirai; Hiroshi Chiba; Masatoshi Itoh; Hidetada Sasaki
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

View more
  1 in total

1.  Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.

Authors:  Yanming Wang; William E Klunk; Manik L Debnath; Guo-Feng Huang; Daniel P Holt; Li Shao; Chester A Mathis
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.